所有图片(4)

文件

COO原产地证书/COA分析证书

SAB1404011

单克隆抗 KRAS 小鼠抗

clone 4F3, purified immunoglobulin, buffered aqueous solution

所有图片(4)

别名:

C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, KI-RAS, KRAS1, KRAS2, NS3

NACRES:

NA.41

比较类似商品

查看完整比较结果

Show Differences

1 of 4

此商品	SAB5700084	SAB4100599	WH0003845M1
Sigma-Aldrich SAB1404011 单克隆抗 KRAS 小鼠抗	Sigma-Aldrich SAB5700084 Anti-KRAS antibody produced in rabbit	Sigma-Aldrich SAB4100599 Anti-KRAS antibody, Mouse monoclonal	Sigma-Aldrich WH0003845M1 单克隆抗 KRAS 小鼠抗
conjugate unconjugated	conjugate -	conjugate unconjugated	conjugate unconjugated
antibody form purified immunoglobulin	antibody form affinity isolated antibody	antibody form purified from hybridoma cell culture	antibody form purified immunoglobulin
clone 4F3, monoclonal	clone polyclonal	clone KRAS-A582, monoclonal	clone 3B10-2F2, monoclonal
form buffered aqueous solution	form buffered aqueous solution	form aqueous solution	form buffered aqueous solution
mol wt antigen ~38.21 kDa	mol wt 21	mol wt antigen predicted mol wt 27.9 kDa	mol wt -

一般描述

c-K-Ras或KRAS（Kirsten大鼠肉瘤2病毒癌基因）是一种小的GTP结合蛋白。编码它的基因位于人染色体12p12.1上。KRAS有两个剪接变体，即KRASA和KRASB（KRAS原癌基因）。KRASA的表达仅限于特定组织，而KRASB广泛表达。

该基因是Kirsten ras癌基因同源物，来自哺乳动物ras基因家族，所编码的蛋白是小GTP酶超家族成员。单个氨基酸的取代造成了活化突变。所产生的转化蛋白与各种恶性肿瘤有关，包括肺腺癌、粘液性腺瘤、胰腺导管癌和结肠直肠癌。选择性剪接产生变体，编码两个同工型，在C末端区域不同。（由RefSeq提供）

免疫原

KRAS（NP_004976, 16 a.a.~ 125 a.a）带有GST标签的部分重组蛋白。仅GST标签的MW为26 KDa。

序列
KSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTV

应用

小鼠抗KRAS单克隆抗体可用于蛋白质印迹。

生化/生理作用

KRAS（Kirsten大鼠肉瘤-2病毒癌基因）突变已与早期直肠癌和结直肠癌相关。该蛋白在信号传导途径中起作用。

KRAS（kirsten大鼠肉瘤2病毒癌基因）与细胞表面受体（包括EGFR）结合后，通过从GDP结合状态循环到GTP结合状态，充当自灭活信号转导子。基因突变导致早期直肠癌预后不良。

外形

溶于pH7.4的磷酸盐缓冲盐水中的溶液

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

ZRB003845

抗-KRas抗体，克隆2J13，ZooMAb^®兔单克隆抗体, recombinant, expressed in HEK 293 cells

储存分类代码

10 - Combustible liquids

WGK

WGK 1

闪点(F)

Not applicable

闪点(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例 T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

请输入1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.

David M Briere et al.

Molecular cancer therapeutics, 20(6), 975-985 (2021-03-17)

KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non-small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12C mutations are smoking-associated transversion mutations associated with high

Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer

Kwak MS, et al.

Medicine, 96(35) (2017)

KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry

Lu J, et al.

Structure, 25(9), 1442-1448 (2017)

The prognostic value of KRAS mutation by cell-free DNA in cancer patients: a systematic review and meta-analysis.

Zhuang R, et al.

PLoS ONE, 12(8), e0182562-e0182562 (2017)

Exploring Targeted Degradation Strategy for Oncogenic KRASG12C.

Mei Zeng et al.

Cell chemical biology, 27(1), 19-31 (2019-12-31)

KRAS is the most frequently mutated oncogene found in pancreatic, colorectal, and lung cancers. Although it has been challenging to identify targeted therapies for cancers harboring KRAS mutations, KRASG12C can be targeted by small-molecule inhibitors that form covalent bonds with cysteine

查看所有相关文献

商品

Oncogenes and Tumor Suppressors Reprogram Metabolism

We present an article about how proliferating cells require the biosynthesis of structural components for biomass production and for genomic replication.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件

单克隆抗 KRAS 小鼠抗

clone 4F3, purified immunoglobulin, buffered aqueous solution

推荐产品

属性

生物来源

质量水平

偶联物

抗体形式

antibody product type

克隆

形式

分子量

species reactivity

technique(s)

同位素/亚型

NCBI登记号

UniProt登记号

运输

储存温度

Gene Information